Advertisement
Advertisement
U.S. markets open in 7 hours 6 minutes
Advertisement
Advertisement
Advertisement
Advertisement

I-Mab (IMAB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
52.75-4.68 (-8.15%)
At close: 04:00PM EST
52.75 0.00 (0.00%)
After hours: 07:51PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close57.43
Open55.88
Bid0.00 x 1400
Ask0.00 x 1400
Day's Range51.83 - 57.25
52 Week Range37.00 - 85.40
Volume366,451
Avg. Volume516,558
Market Cap4.117B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.05
Earnings DateAug 31, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est96.05
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-51% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for IMAB

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • I-MAB
    Analyst Report: I-MabI-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia.
    Rating
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more
Advertisement
Advertisement